Research Article

Decreased Expression of MPC2 Contributes to Aerobic Glycolysis and Colorectal Cancer Proliferation by Activating mTOR Pathway

Manzila Kuerbanjiang,1 Lei Gu,1 Chunjie Xu,1 Wen Ting Xu,2 Siyuan Wen,1 Hanbing Xue,3 and Qing Xu1

1Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2China Welfare Association International Peace Maternal and Child Health Care Center, Shanghai, China
3Department of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai, China

Correspondence should be addressed to Hanbing Xue; medxue@126.com and Qing Xu; renjixuqing@163.com

Received 28 December 2020; Revised 9 February 2021; Accepted 5 March 2021; Published 15 March 2021

Academic Editor: Yan-Qiu Yu

Copyright © 2021 Manzila Kuerbanjiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mitochondrial Pyruvate Carrier 1 (MPC1), one of the rate-limiting proteins involved in glycolysis metabolism, has been demonstrated as a tumor inhibitor in several cancers. This study was conducted with the aim of exploring the role and underlying mechanisms of MPC2 in colorectal cancer (CRC). Here, we found that MPC2 expression was decreased in CRC samples. According to the analysis on our TMA data, lower expression of MPC2 is correlated with a higher incidence of distant metastasis and lymph node invasion, bigger tumor size, low survival rate of patients, and advanced T stages. Functionally, in vivo/vitro experiments showed that MPC2 knockdown induced CRC cell proliferation and growth, while MPC2 overexpression inhibited the proliferation and growth of CRC. Further study demonstrated that MPC2 knockdown resulted in aerobic glycolysis in CRC cells. Similarly, MPC2 overexpression in CRC cells also caused inhibited aerobic glycolysis. Further study found that MPC2 knockdown in CRC cell lines activated the mTOR signaling pathway, and the addition of rapamycin reversed the promoting effect of MPC2 knockdown on CRC proliferation and glycolysis. Likewise, the addition of MHY1485 also reversed the MPC2 overexpression’s role in hindering aerobic glycolysis in CRC cells. Collectively, our study established that low expression of MPC2 led to CRC growth as well as aerobic glycolysis through the regulation of the mTOR pathway in CRC cells, indicating a potential biomarker and therapy target for CRC.

1. Introduction

Colorectal Carcinoma (CRC), as a prevailing type of cancer worldwide, ranked the third-highest cancer-related death factor in the United States [1, 2]. The prognosis of CRC patient stage at diagnosis and 5-year survival rate of CRC patients at stage 1 and stage 2 could reach 70%, while less than 10% for stage IV [3]. Therefore, prognostic biomarkers as well as therapy target are urgent to be identified to improve CRC patients’ survival.

Mitochondrial Pyruvate Carrier (MPC) is a heterologous complex containing two members, MPC1 and MPC2 [4–7]. The complex localizes in the integral inner mitochondrial membrane and is in charge of conducting pyruvate from the cytosol into the mitochondria, one of the rate-limiting steps in glycolysis, and links glycolysis with mitochondrial oxidative phosphorylation (OXPHOS) [5, 8]. An increasing number of studies showed downregulated expression of the MPC complex in different cancers, such as prostate cancer and hepatocellular carcinoma, and restoring MPC2 in human tumor cells inhibited melanoma cell proliferation and migration [9–11]. Moreover, a study showed that MPC2 predicted poor survival in patients with isocitrate dehydrogenase-mutant glioma [12], although the potential
role of MPC2 in cancer, the clinical relevance, and molecular mechanism underlying its influence on CRC progression remain unknown.

Metabolic reprogramming has been considered one of the hallmarks of cancer, with the Warburg effect being a common feature [13, 14]. Warburg effect is featured as high glucose uptake and utilization to provide cancer with increased bioenergetics and biosynthesis in anorexic and hypoxic conditions [8]. Therefore, the association and potential regulatory mechanism of glycolysis in cancer are to be studied.

In this study, we showed low expression of MPC2 CRC samples, which resulted in aerobic glycolysis via activating the mTOR pathway and promoted CRC proliferation.

2. Materials and Methods

2.1. Database, Patients, and Clinical Tissue Specimens. We analyzed the MPC2 mRNA expression in 327 samples (including 286 CRC tissues and 41 tissues adjacent to cancer) from The Cancer Genome Atlas (TCGA) database and 17 matched samples from GEO [15]. OncoLnc (http://www.oncolnc.org) was used to link survival data of patients in the TCGA database to normalized MPC2 mRNA; patients were divided into the high group (top thirty percentile) and the low group (lower thirty percentile). The Kaplan plot curves and the log-rank p value were analyzed automatically by OncoLnc. The tissue microarray chip consists of three hundred ninety-two CRC pairs of adjacent noncancerous and tumor samples from patients diagnosed with CRC in Renji Hospital, China. The ethics committee of Renji Hospital approved the study, and every patient was assigned informed consent.

2.2. Cell Culture. LOVO, HCT116, RKO, and SW620 as human colon carcinoma cell lines were provided by ATCC. Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) with 10% fetal bovine serum (FBS, Gibco) as well as 1% penicillin and 1% streptomycin was used to culture the cells in an incubator at 5% CO₂ and 37°C.

2.3. Lentivirus Transfection. Lentiviral vectors for the short-hairpin RNA (shRNA) for MPC2 were generated by GenePharma (Shanghai, China). We transferred the shRNA sequence for MPC2 into CRC cell lines and generated shRNA-MPC2#1 and shRNA-MPC2#2 with 10 mg/mL polybrene (Sigma, H9268). Moreover, the negative control was set as shNC-MPC2. The expression of MPC2 (MPC2-OE) was generated by transfecting full-length human MPC2 cDNA, where the negative control (vector) was lentivirus-NC. Supplementary Table S1 lists the sequences. Transfection of shRNA was performed according to the manufacturer’s protocol.

2.4. RNA Extraction and RT-qPCR. Total RNA was extracted from cell samples by the Simply P Total RNA Extraction Kit (BSC51S1, Bioer Technology, China). Reverse transcription to cDNA was conducted by the PrimeScript RT reagent Kit (RR037Q, Takara Biotech, China). The target gene’s relative expression to 18S RNA was calculated by the ΔΔCt method. Supplementary Table S1 lists all primers designed for the RT-qPCR in this study.

2.5. Protein Extraction and Western Blotting. The RIPA buffer (Sangon Biotech, China), as well as 1% inhibitors of phosphatase and protease (Sangon Biotech, China), was applied to extract total protein. A BCA Protein Assay Kit (A53225, Thermo Fisher) was selected for the measurement of protein concentration. Western blotting was performed as previously described. Such primary antibodies as MPC2 (1:1000, ab236584, Abcam, Cambridge, MA), β-actin (1:1000, 20536-1-AP, Proteintech, China), mTOR (1:1000, 2983, CST, USA), and p-mTOR (1:1000, 2971, CST, USA) were adopted. Secondary antibodies were HRP-conjugated goat anti-rabbit IgG provided by Proteintech, China (1:5000, SA00001-2).

2.6. Immunohistochemistry (IHC). IHC staining was conducted following a standard procedure as previously described [16]. Tissues were embedded with paraffin and incised into 4 μm thick sections. Dewaxing the sections by xylene and hydrating by alcohol were then performed, followed by antigen retrieval via sodium citrate (Sangon Biotech, China) and endogenous peroxidase blocking by 0.3% H₂O₂. Bovine serum albumin (BSA, Sangon Biotech) was used to block nonspecific sites, and MPC2 (1:100, ab236584, Abcam) and Ki67 (1:100, 27309-1-AP, Proteintech, China) were used to incubate the slices for 8 hrs then with secondary antibody (1:100, SA00001-2, Proteintech, China) for 60 minutes. The DAB Substrate kit (# 8059S, CST) was used for visualization; then, nuclei were stained with hematoxylin. Further dehydration was performed with alcohol and sealing with neutral resin. IHC stainings were qualified using a grade scoring method, and it was scored from 1 to 4 as no, weak, moderate, and strong staining, respectively [17, 18]. Besides, samples were divided into two groups according to their MPC2 staining: the low level group (scores 1 and 2) and the high level group (scores 2 and 3).

2.7. Cell Growth and Colony Formation Assays. The cell viability was measured by the Cell Counting Kit-8 (CK04, Dojindo, Japan) using the method as previously described [19]. Cells were inoculated with suspension of 100 μL/well (3000 cells/well) in a 96-well plate and cultured in an incubator (at 37°C, 5% CO₂) for 24, 48, 72, and 96 h after the treatment. After being added with CCK-8 solution (10 μL/well), the cells were incubated for 2 h at 37°C. Then, the absorbance at 450 nm was measured in a microplate reader.

For the clonogenic assay, we used 6-well plates (3000 cells/well) to inoculate cells. After two weeks, fixation by 4% paraformaldehyde and staining by 0.5% crystal violet for 30 min were performed.

2.8. Extracellular Acidification and Oxygen Consumption Rate Assays. Regarding the cultured cells, the assays for the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were detected as previously reported under the support of the Seahorse XF96 Flux Analyzer (Seahorse Bioscience, Agilent) following the protocol of the manufacturer [20]. The Seahorse XF Cell Mito Stress Test Kit and Seahorse XF Glycolysis Stress Test Kit (103010-100 and 103020-100, Agilent Technologies, USA) were used to examine OCR.
and ECAR, respectively. To be specific, we inoculated cells in an XF 96-well plate (1 \times 10^4/well) with the indicated treatment. After baseline measurements, for the glycolytic stress test, 10 mmol/L glucose, 1 mmol/L oligomycin (oxidative phosphorylation inhibitor), and 50 mmol/L 2-deoxyglucose (2-DG, oxidative phosphorylation inhibitor) were applied to every well in order at a given time. In the mitochondrial stress test, 1 mmol/L oligomycin, 1 mmol/L FCCP (reversible inhibitor of oxidative phosphorylation), 0.5 mmol/L rotenone (Rote, the mitochondrial complex I inhibitor), and 0.5 mmol/L actinomycin A (AA, mitochondrial complex III inhibitor) were sequentially added to the wells. Seahorse XF-96 Wave software was adopted for data analysis. Glycolytic flux and maximal respiratory capacity were measured as previously reported [21, 22]. An increase in ECAR after the glucose treatment indicated glycolytic flux; total elevation in OCR above basal respiration after FCCP treatment indicated maximal respiratory capacity. OCR and ECAR were measured in pmols/minute and mpH/minute, respectively.

2.9. Tumor Orthotopic Xenograft Model. The orthotopic xenograft model for CRC was generated following the method previously reported [23]. We used 0.5% pentobarbital to anesthetize nude mice. The abdominal cavity was exposed through a midline laparotomy. 1 \times 10^6 luciferase-expressing HCT116 or HT29 cell suspension was injected directly into the submucosa of the ileocecum. The growth of the tumor was monitored by the IVIS spectrum (Caliper Life Science, USA) intraperitoneal injection of D-luciferin (150 mg; Promega, catalog) and gas anesthesia. Living Image

---

**Figure 1: MPC2 is downregulated in tumor tissue and correlated with a poor prognosis of Colorectal Carcinoma (CRC).** (a) The mRNA expression of MPC2 in the CRC tissues compared to tissue adjacent to cancer in The Cancer Genome Atlas (TCGA) database. (b) The mRNA expression of MPC2 in the CRC tissues compared to paired tissue adjacent to cancer selected from the GDS4382 database. (c) Overall survival analyzed by a log-rank test and the Kaplan-Meier method according to the MPC2 mRNA expression from the TCGA dataset. (d) Representative IHC images for MPC2 expression of normal tissues and matched CRC tissues from TMA. (e) IHC score of MPC2 expression of normal tissues and matched CRC tissues from TMA. (f) Overall survival analyzed through the log-rank test and Kaplan-Meier method based on the MPC2 mRNA expression from TMA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Software (version 4.5.3) was used to quantify the luciferin emission. Four weeks later, we sacrificed mice, the xenograft tumor of which was separated, weighed, and fixed with 4% paraformaldehyde. The International Standards of Animal Welfare were followed during the whole animal studies, which were approved by the Research Ethics Committee of Renji Hospital.

2.10. Statistical Analysis. We repeated all in vitro experiments no less than three times. GraphPad Prism (San Diego, CA) was applied to the overall statistical analyses. To figure out how categorical clinical variables in CRC patients correlated with MPC2 expression, Student's t-test or chi-squared analysis was applied to calculate the measurement data such as age and tumor size or to calculate categorical variables including sex and the presence of patients' distant metastasis and lymph node invasion and to rank data like T stages. The two-way ordered categorical data were calculated by Spearman's rank correlation. The data generated by patient survival curves were analyzed by the log-rank test as well as the Kaplan-Meier method. The mean ± SD was adopted to express the measurement data. The significant level in this study is 5%. The significant levels are the following: *p value < 0.05, **p value < 0.01, ***p value < 0.001, and ****p value < 0.0001.

3. Results

3.1. MPC2 Was Downregulated in CRC Tissue and Correlated with Poor Prognosis of CRC. According to the dataset from TCGA and the GEO, compared with paired tissue adjacent to cancer, the mRNA expression of MPC2 decreased in CRC tissues (Figures 1(a) and 1(b)). Notably, Kaplan-Meier survival analysis indicated shorter overall survival for patients that had a lower level of MPC2 expression (p = 0.01) (Figure 1(c)). IHC staining in a TMA containing 392 CRC specimens and paired corresponding tissue adjacent to cancer was performed to validate the protein level of MPC2. The expressions were scored according to the intensity. The result of TMA analysis also showed substantially lower MPC2’s protein expression in CRC tissues than those in tissues adjacent to cancer, and CRC tissues manifested a lower staining score (Figures 1(d) and 1(e)). Therefore, our data showed downregulation of MPC2 expression in CRC tissues as compared to adjacent tissues. The association between MPC2 expression and patients’ clinicopathological characteristics was analyzed to explore the clinical significance of MPC2. Table 1 implies the negative correlation of tumor size, incidence of distant metastasis, and lymph node invasion, as well as T staging, with the expression of MPC2. Besides, the survival of patients with lower MPC2 expression was lower than that of patients with higher MPC2 expression levels, as demonstrated by Kaplan-Meier survival analysis (Figure 1(f)).

3.2. MPC2 Suppressed Proliferation of CRC Cells In Vitro and In Vivo. Next, we measured the expression of protein MPC2 and mRNA in several CRC cell lines (Figure 2(a), Supplementary Figure S1A). HCT116 and RKO cells were selected for investigating the effect of MPC2 knockdown because of their relatively higher expressions, while HT29 and SW620 cells were selected for investigating the effect of MPC2 overexpression on CRC cells according to the lower expressions. Both mRNA and protein expressions of MPC2 were markedly downregulated after transfecting with shRNA#1 (shMPC2#1) and shRNA#2 (shMPC2#2) in HCT116 and RKO cells and upregulated after transfecting with MPC2-OE in HT29 and SW620 cells (Figures 2(b) and 2(c), Supplementary Figure S1B). Besides, as MPC is a complex, we further detected the expression of MPC1 after MPC2 knockdown or overexpression. The result showed neither mRNA level nor protein level of MPC1 altered with MPC2 overexpression on CRC cells according to the complex, we further detected the expression of MPC1 after MPC2 knockdown or overexpression. The result showed neither mRNA level nor protein level of MPC1 altered with MPC2-OE in HT29 and SW620 cells (Figures 2(b) and 2(c)).

Then, we assessed the proliferation of CRC cells after MPC2 knockdown or overexpression by the CCK8 assay. It was found that knockdown of MPC2 increased proliferation of RKO and HCT116 cells compared with the control (shNC) group (Figure 2(d)), while overexpression of MPC2 decreased cell proliferation in HT29 and SW620 cells compared with the control (Supplementary Figure S1G). Further, colony formation assays showed more colonies in the shMPC2#1 and shMPC2#2 groups (Figure 2(e)). These data suggested that MPC2 impaired CRC cell proliferation in vitro.

The role of MPC2 in CRC growth was further assessed by an orthotopic tumor model. The sh-MPC2 (using shRNA#2) group displayed distinctly higher tumor weight than the control group, while that of the MPC2-OE group was lower compared to the vector group (Figures 2(f) and 2(g)). Further, IHC assays of Ki67 in an orthotopic tumor revealed that knockdown of MPC2 promoted Ki67 expression while...
Figure 2: Continued.
overexpression of MPC2 inhibited the expression (Figure 2(h)). These data collectively suggested the role of MPC2 in suppressing CRC growth both in vitro and in vivo.

3.3. Downregulated MPC2 Expression Enhanced Glycolysis in CRC. We performed GSEA for examining the mechanism behind downregulated MPC2 promoting CRC growth. We divided the samples from the TCGA database into the MPC-high group and the MPC2-low group based on the MPC2 expression. The results showed a negative association of MPC2 expression with glycolysis and a positive association of MPC-high group and the MPC2-low group based on the divided the samples from the TCGA database into the CRC.

3.4. MPC2 Reduced Glycolysis Level via mTOR Pathway in CRC Cells. According to the result of the GSEA mentioned above, MPC2 expression was found to negatively correlate with the mTOR pathway activity (Figure 4(a)). Additionally, the mTOR signaling pathway plays a key part in regulating cell proliferation as well as glycolysis [24, 25]. Therefore, further study on the mTOR pathway was undertaken. Western blot showed that MPC2 knockdown exhibited a higher p-mTOR expression compared to the control group, while MPC2 overexpression showed a lower p-mTOR expression (Figure 4(b) and Supplementary Figure S4A). In addition, the activation of the mTOR pathway induced by MPC2 knockdown was reversed by the addition of rapamycin, an inhibitor of the mTOR pathway, while the decrease of the p-mTOR level caused by overexpressing MPC2 was reversed by the addition of mTOR activator MHY1485 (Figure 4(b) and Supplementary Figure S4A). The result showed that the effects of silencing MPC2 by shRNA#2 on glucose uptake, lactate production, glycolysis-related gene expression, ECAR, and OCR were significantly abolished by the mTOR inhibitor (Figures 4(c)–4(f), Supplementary Figure S4B–C). Taken together, these findings indicated that MPC2 reduced glycolysis through the mTOR pathway.

4. Discussion
In this study, we found that downregulated MPC2 promotes CRC growth by enhancing glycolysis via the mTOR
Glycolysis

Oxidative phosphorylation

Relative lactate production

Relative glucose consumption

(a)

Relative mRNA expression

(b)

(c)

(d)

Figure 3: Continued.
pathway. In specific, we confirmed that MPC2 expression is downregulated in CRC tissue from an online database and TMA of our hospital, and it is negatively correlated with aggressive clinical characteristics of patients. In addition, our study demonstrated that inhibiting MPC2 promoted CRC proliferation using in vitro and in vivo models. Mechanistically, we found that downregulated MPC2 promoted glycolysis via the mTOR pathway.

A recent study found that the MPC2 mRNA level predicted a worsened survival in patients with isocitrate dehydrogenase-mutant glioma using an online database [12]. In addition, another research reported that the MPC2 level was lower in prostate cancer cells and tissue, and MPC2 predicted a better OS of patients with prostate cancer [9]. In our study, we showed the first time that MPC2 was lower in CRC tissue, and downregulated MPC2 predicted a worse OS for CRC patients using a larger amount of paired patients’ tissue.

Metabolism relies on glycolysis and mitochondrial OXPHOS to produce ATP and provides energy in normal conditions. In proliferating cancer cells, aerobic glycolysis is the main process to produce ATP and supports biosynthesis even if there is enough oxygen, which is called Warburg effect [26]. This kind of metabolic reprogramming advantages cancer cell proliferation by providing energy quicker, which is recognized as a common feature of cancer, including CRC [27]. Moreover, most key molecules related to glycolysis are involved in tumor progression [28]. A glycolysis gene expression analysis of CRC showed increased glucose intake along with aerobic glycolysis in CRC tissue, and a high glycolytic character was correlated with a poorer prognosis in CRC patients [29]. In line with these previous studies, our data demonstrated that downexpression of MPC2 contributed to aerobic glycolysis in CRC cells.

The PI3K/Akt/mTOR pathway has been demonstrated as one of the central regulators of glycolysis and cancer proliferation [24, 25]. Regarding the potential mechanisms of glycolysis in CRC cells, an increasing number of studies found that activation of the mTOR pathway directly correlates with increased glycolysis in tumor cells compared with normal cells [30, 31]. A recent study demonstrated that activated Purinergic Receptor P2Y2 (P2RY2) contributed to the activation of the PI3K-mTOR pathway thus enhancing cancer glycolysis in pancreatic ductal adenocarcinoma [32]. In addition, in our study, GSEA also indicated an association between MPC2 expression and mTOR pathway. Further exploration showed that the inhibitor of the mTOR pathway could attenuate the glycolysis induced by silencing of MPC2, indicating that mTOR may participate in the role of MPC2 in glycolysis. Therefore, MPC2 may participate in glycolysis via the mTOR pathway in CRC cells. Our study showed correlation of MPC2 and mTOR pathway for the first time. A recent report revealed that extracellular lactate, the product of pyruvate, activated the Akt-mTOR signaling pathway to promote cell proliferation and prevent cell death. In addition, lactate could fuel the TCA cycle for amino acid synthesis, resulting in mTORC1 activation in normoxic cancer cells [33, 34]. Moreover, a previous study found MPCL expression negatively associated with HIF1α expression in human RCC [35]. HIF1α is one of the key regulators in glycolysis as well as downstream of the mTOR pathway [36]. In combination with our current results, we speculate that MPC2 may inhibit

Figure 3: MPC2 expression suppressed glycolysis in CRC cells. (a) GSEA of MPC2 expression in CRC samples from the TCGA database. (b) Lactate production and glucose intake of CRC cells transfected with shNC or shMPC2 (relative to shNC). (c) Relative mRNA levels of glycolysis-related genes of HCT116 (left) as well as RKO cells (right) transfected with shNC or shMPC2 (relative to shNC). (d) Glycolytic pathway. In speci

(c)
Figure 4: Continued.
glycolysis via the mTOR/HIF1α axis, which would be further confirmed in the future study.

In addition to the proliferation inhibiting role of MPC2, a study also investigated MPC1 losing promoted migration and invasion in RCC [35]. In our study, we also found that MPC2 expression is negatively associated with the incidence of lymph node invasion and liver metastasis. However, our study focused on the role of MPC2 in CRC growth. In the future, we would further explore whether MPC2 inhibits migration and invasion thus affecting liver metastasis in CRC using mouse models.

In summary, our results demonstrated decreased expression of MPC2 in CRC and its correlation with a poor prognosis of CRC patients. In addition, MPC2 inhibited CRC growth in vivo and in vitro. Moreover, MPC2 reduced glycolysis by inhibiting the mTOR pathway. Our study suggested a potential role of MPC2 in CRC diagnosis and a promising therapeutic target. The further underlying molecular mechanism remains to be determined and merits further study.

5. Conclusions

In conclusion, we found downregulated MPC2 expression in CRC tissues, as well as a negative association of the expression with distant metastasis, patients’ survival, lymph node invasion, T stage, and tumor size. Thus, we also found that downregulated MPC2 promoted CRC growth by inducing glycolysis via the mTOR pathway. Our study suggested a potential role of MPC2 in CRC diagnosis and a promising therapeutic target.

Data Availability

The data supporting the above findings can be accessed under the approval of the corresponding authors.

Conflicts of Interest

The authors declare no conflict of interest concerning the publication of this paper.

Authors’ Contributions

Manzila Kuerbanjiang, Lei Gu, Chunjie Xu, and Wen Ting Xu contributed equally to this work.

Acknowledgments

The present research was funded by the National Natural Science Foundation of China (82072671).

Supplementary Materials

Supplementary Figure S1: A. The mRNA expression of MPC2 in several CRC cell lines performed by qRT-PCR. B. The overexpression efficiency in HT29 and SW620 cells showed using qRT-PCR. C. The viability of HT29 (left) and SW480 cells (right) transfected with MPC2-OE or vector detected with CCK-8 assay. C. The mRNA expression of MPC1 in HCT116 and RKO cells with MPC2 knockdown by shRNA measured by qRT-PCR (relative to shNC group). D. The mRNA expression of MPC1 in SW620 and HT29 cells with MPC2 overexpression measured by qRT-PCR (relative to vector group). E. The protein expression of MPC1 in

---

**Figure 4:** MPC2 reduced glycolysis level via mTOR pathway in CRC cells. (a) GSEA from CRC tissues from the TCGA database. (b) Western blotting images of phospho-mTOR (p-mTOR) and mTOR in HCT116 and RKO cells with shNC or shMPC2 transfection and/or rapamycin treatment (50 nmol/L). (c) Lactate production and glucose consumption of CRC cells with shNC or shMPC2 transfection and/or rapamycin. (d) Relative mRNA expression of glycolysis-related genes of HCT116 and RKO cells with shNC or shMPC2 transfection and/or rapamycin treatment. (e) Glycolytic function of RKO and HCT116 cells under the indicated treatments as measured by ECAR. (f) Mitochondrial stress test RKO cells (right) and HCT116 cells (left) under the indicated treatments as measured by oxygen consumption rate (OCR). *p < 0.05, **p < 0.01.
HCT116 and RKO cells with MPC2 knockdown by shRNA measurement by western blotting. G. The viability of SW480 cells (right) and HT29 cells (left) through the transfection by MPC2-OE or vector detected with CCK-8 assay. Supplementary Figure S2: MPC2 knockdown promoted glycolysis in CRC cells. A. Glycolytic flux measured by ECAR in HCT116 and RKO cells with MPC2 knockdown with/or MPC2 overexpression. B. Maximal respiratory capacity measured by OCR in HCT116 and RKO cells with MPC2 knockdown with/or MPC2 overexpression. Supplementary Figure S3: MPC2 overexpression inhibited glycolysis in CRC cells. A. Western blot analysis of phospho-mTOR (p-mTOR) with/or rapamycin treatment (50 nmol/L). Supplementary Figure S4: MPC2 reduced p-mTOR level in CRC cells. B. Maximal respiratory capacity measured by OCR in HCT116 and RKO cells with vector and MPC2 overexpression measured by ECAR in HCT116 and RKO cells with vector or MPC2-OE (relative to vector). C. Relative mRNA levels of glycolysis-related genes in HT29 cells (right) and SW620 cells (left) through the transfection via vector or MPC2-OE (relative to shNC). D. Glycolytic function of SW620 (left) and HT29 cells (right) under the indicated treatments showed by extracellular acidification rate (ECAR). E. Mitochondrial stress tests glycolytic function of SW620 (left) and HT29 cells (right) in MPC2 knockdown and/or MPC2 overexpression under the indicated treatments as measured by oxygen consumption rate (OCR). Supplementary Figure S4: MPC2 reduced p-mTOR level in CRC cells. A. Western blot analysis of phospho-mTOR (p-mTOR) and mTOR in SW620 and RKO cells with vector and MPC2 overexpression transfection and/or MHY1485 treatment (10 μM, 4 h). B. Glycolytic flux measured by ECAR in HCT116 and RKO cells with MPC2 knockdown with/or rapamycin. B. Maximal respiratory capacity measured by OCR in HCT116 and RKO cells with MPC2 knockdown with/or rapamycin treatment (50 nmol/L). Supplementary Table S1: the number and percentage of IHC score in 392 cases of normal tissues and matched CRC tissues. Supplementary Table S2: sequences of shRNA and primer. (Supplementary Materials)

References

[1] R. L. Siegel, K. D. Miller, S. A. Fedewa et al., “Colorectal cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 3, pp. 177–193, 2017.
[2] H. Brody, "Colorectal cancer," Nature, vol. 521, no. 7551, p. S1, 2015.
[3] J. B. O’Connell, M. A. Maggard, and C. Y. Ko, “Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging,” Journal of the National Cancer Institute, vol. 96, no. 19, pp. 1420–1425, 2004.
[4] D. K. Bricker, E. B. Taylor, J. C. Schell et al., “A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans,” Science (New York, NY), vol. 337, no. 6090, pp. 96–100, 2012.
[5] S. Herzig, E. Raemy, S. Montessuit et al., “Identification and functional expression of the mitochondrial pyruvate carrier,” Science (New York, NY), vol. 337, no. 6090, pp. 93–96, 2012.
[6] T. Bender, G. Pena, and J. C. Martinou, “Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes,” The EMBO Journal, vol. 34, no. 7, pp. 911–924, 2015.
[7] J. R. Colca, W. G. McDonald, G. S. Cavey et al., “Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)—relationship to newly identified mitochondrial pyruvate carrier proteins,” PloS one, vol. 8, no. 5, article e61551, 2013.
[8] A. J. Rauckhorst and E. B. Taylor, "Mitochondrial pyruvate carrier function and cancer metabolism," Current Opinion in Genetics & Development, vol. 38, pp. 102–109, 2016.
[9] X. Li, Y. Ji, G. Han et al., “MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer,” BMC Cancer, vol. 16, no. 1, p. 894, 2016.
[10] Y. Deng, H. Li, X. Yin et al., “C-terminal binding protein 1 modules cellular redox via feedback regulation of MPC1 and MPC2 in melanoma cells,” Medical science monitor: international medical journal of experimental and clinical research, vol. 24, pp. 7614–7624, 2018.
[11] X. Ma, Y. Cui, H. Zhou, and Q. Li, “Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients,” Oncology Letters, vol. 15, no. 6, pp. 9110–9116, 2018.
[12] M. Karsy, J. Guan, and L. E. Huang, “Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma,” Journal of Neurosurgery, vol. 130, no. 1, pp. 56–66, 2018.
[13] W. H. Koppenol, P. L. Bounds, and C. V. Dang, “Otto Warburg’s contributions to current concepts of cancer metabolism,” Nature Reviews Cancer, vol. 11, no. 5, pp. 325–337, 2011.
[14] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg effect: the metabolic requirements of cell proliferation,” Science, vol. 324, no. 5930, pp. 1029–1033, 2009.
[15] A. Khamsa, T. Ishikawa, K. Shimokawa et al., “Screening for epigenetically masked genes in colorectal cancer using 5-Aza-2’-deoxycytidine, microarray and gene expression profile,” Cancer Genomics & Proteomics, vol. 9, no. 2, pp. 67–75, 2012.
[16] X.-M. Yang, X.-Y. Cao, P. He et al., “Overexpression of Rac GTPase activating protein 1 contributes to proliferation of cancer cells by reducing Hippo signaling to promote cytokinesis,” Gastroenterology, vol. 155, no. 4, pp. 1233–1249.e22, 2018.
[17] N. Chen, G. Zhao, X. Yan et al., “A novel FL11 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1,” Genome Biology, vol. 19, no. 1, p. 218, 2018.
[18] W. Weichert, A. Röske, V. Gekeler et al., “Association of pattern of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis,” The Lancet Oncology, vol. 9, no. 2, pp. 139–148, 2008.
[19] W. Luo, F. Gao, S. Li, and L. Liu, “FoxM1 promotes cell proliferation, invasion, and stem cell properties in nasopharyngeal carcinoma,” Frontiers in Oncology, vol. 8, p. 483, 2018.
[20] S.-H. Jiang, J. Li, F.-Y. Dong et al., “Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice,” Gastroenterology, vol. 153, no. 1, pp. 277–291.e19, 2017.
[21] L. Gibellini, L. Losi, S. De Biasi et al., “LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells,” Frontiers in Oncology, vol. 8, 2018.
[22] H. V. Vangapandu, O. Havranek, M. L. Ayres et al., “B-cell receptor signaling regulates metabolism in chronic lymphocytic leukemia,” Molecular cancer research: MCR, vol. 15, no. 12, pp. 1692–1703, 2017.
[23] C. Xu, G. Tian, C. Jiang et al., “NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6,” Cell Death & Disease, vol. 10, no. 3, p. 217, 2019.

[24] B. Zhivotovsky and S. Orrenius, “The Warburg effect returns to the cancer stage,” Seminars in Cancer Biology, vol. 19, no. 1, pp. 1–3, 2009.

[25] R. Courtney, D. C. Ngo, N. Malik, K. Veroreis, S. M. Tortorella, and T. C. Karagiannis, “Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K,” Molecular Biology Reports, vol. 42, no. 4, pp. 841–851, 2015.

[26] L. M. R. Ferreira, “Cancer metabolism: the Warburg effect today,” Experimental and Molecular Pathology, vol. 89, no. 3, pp. 372–380, 2010.

[27] R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, and C. B. Thompson, “The biology of cancer: metabolic reprogramming fuels cell growth and proliferation,” Cell Metabolism, vol. 7, no. 1, pp. 11–20, 2008.

[28] R. Camarda, A. Y. Zhou, R. A. Kohnz et al., “Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer,” Nature Medicine, vol. 22, no. 4, pp. 427–432, 2016.

[29] F. Graziano, A. Ruzzo, E. Giacomini et al., “Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer,” The Pharmacogenomics Journal, vol. 17, no. 3, pp. 258–264, 2017.

[30] K. Masui, K. Tanaka, D. Akhavan et al., “mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc,” Cell Metabolism, vol. 18, no. 5, pp. 726–739, 2013.

[31] Q. Tran, H. Lee, J. Park, S. H. Kim, and J. Park, “Targeting cancer metabolism-revisiting the Warburg effects,” Toxicological research, vol. 32, no. 3, pp. 177–193, 2016.

[32] L. P. Hu, X. X. Zhang, S. H. Jiang et al., “Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 25, no. 4, pp. 1318–1330, 2019.

[33] E. Allen, P. Mieville, C. M. Warren et al., “Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling,” Cell Reports, vol. 15, no. 6, pp. 1144–1160, 2016.

[34] L. Pisarsky, R. Bill, E. Fagiani et al., “Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy,” Cell Reports, vol. 15, no. 6, pp. 1161–1174, 2016.

[35] X.-P. Tang, Q. Chen, Y. Li et al., “Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma,” Laboratory Investigation, vol. 99, no. 2, pp. 191–199, 2019.

[36] G. L. Semenza, “HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3664–3671, 2013.